Gene Products, tat
-
Subject Areas on Research
- A comparison of regulatory features in primate lentiviruses.
- A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo.
- A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
- A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription.
- Activation of tat-defective human immunodeficiency virus by ultraviolet light.
- Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.
- An in vitro transcription system that recapitulates equine infectious anemia virus tat-mediated inhibition of human immunodeficiency virus type 1 Tat activity demonstrates a role for positive transcription elongation factor b and associated proteins in the mechanism of Tat activation.
- Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes.
- Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates.
- CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.
- Canine cyclin T1 rescues equine infectious anemia virus tat trans-activation in human cells.
- Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke.
- Concerted motions in HIV-1 TAR RNA may allow access to bound state conformations: RNA dynamics from NMR residual dipolar couplings.
- Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
- Does HIV-1 Tat induce a change in viral initiation rights?
- Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain?
- Durhamycin A, a potent inhibitor of HIV Tat transactivation.
- Evidence that Par-4 participates in the pathogenesis of HIV encephalitis.
- Fluorescent peptide displacement as a general assay for screening small molecule libraries against RNA.
- Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells.
- Functional analysis of the Tat trans activator of human immunodeficiency virus type 2.
- Functional characterization of a complex protein-DNA-binding domain located within the human immunodeficiency virus type 1 long terminal repeat leader region.
- Functional differences between human and bovine immunodeficiency virus Tat transcription factors.
- Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators.
- Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
- Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing.
- Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.
- Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus.
- HIV-1 auxiliary proteins: making connections in a dying cell.
- Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism.
- Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
- Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex.
- Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein.
- Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins.
- Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.
- Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.
- Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1.
- Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.
- Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.
- Peptide-derivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization.
- Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation.
- Phosphorylation of the rev gene product of human immunodeficiency virus type 1.
- Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
- Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.
- Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.
- Principles and applications of a Tat-based assay for analyzing specific RNA-protein interactions in mammalian cells.
- RNA-sequence-mediated gene regulation in HIV-1.
- Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.
- Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
- Regulation of 2',5'-oligoadenylate synthetase gene expression by interferons and platelet-derived growth factor.
- Sequence requirements for Rev multimerization in vivo.
- Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia.
- Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.
- Subcellular localization of the human immunodeficiency virus trans-acting art gene product.
- TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation.
- TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance.
- Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling.
- The HIV-1 Tat protein: an RNA sequence-specific processivity factor?
- The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
- The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals.
- Tracking mesenchymal stromal cells using an ultra-bright TAT-functionalized plasmonic-active nanoplatform.
- Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.
- Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.
- Utilization of a mammalian cell-based RNA binding assay to characterize the RNA binding properties of picornavirus 3C proteinases.